A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) | |
Zhou, Caicun; Huang, Yunchao; Wang, Donglin; An, Changshan; Zhou, Fuxiang; Li, Yali; Chen, Gongyan; Wu, Changping; He, Jianxing; Wu, Gang | |
刊名 | CLINICAL LUNG CANCER
![]() |
2016 | |
卷号 | 17期号:[db:dc_citation_issue]页码:119-127 |
关键词 | Long-acting PEG-rhG-CSF Safety Clinical trial Efficacy Granulocyte-colony stimulating factor |
ISSN号 | 1525-7304 |
DOI | [db:dc_identifier_doi] |
URL标识 | 查看原文 |
WOS记录号 | [DB:DC_IDENTIFIER_WOSID] |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3229538 |
专题 | 西安交通大学 |
推荐引用方式 GB/T 7714 | Zhou, Caicun,Huang, Yunchao,Wang, Donglin,et al. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)[J]. CLINICAL LUNG CANCER,2016,17([db:dc_citation_issue]):119-127. |
APA | Zhou, Caicun.,Huang, Yunchao.,Wang, Donglin.,An, Changshan.,Zhou, Fuxiang.,...&Xia, Jielai.(2016).A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).CLINICAL LUNG CANCER,17([db:dc_citation_issue]),119-127. |
MLA | Zhou, Caicun,et al."A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)".CLINICAL LUNG CANCER 17.[db:dc_citation_issue](2016):119-127. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论